CTOP

Research use only, not for human use.

Potent and selective μ opioid receptor antagonist (Ki values are 0.96 and >10,000 nM for μ and δ receptors respectively). Causes behavioral effects on central administration in vivo. Also increases K+ currents in rat locus ceruleus neurons in vitro via a μ receptor independent mechanism.

Potent and selective μ opioid receptor antagonist (Ki values are 0.96 and >10,000 nM for μ and δ receptors respectively). Causes behavioral effects on central administration in vivo. Also increases K+ currents in rat locus ceruleus neurons in vitro via a μ receptor independent mechanism.

——

CTOP (0-0.5 nmol, ICV, once) antagonizes the analgesic effect of morphine in a dose-dependent manner.CTOP (0-2 nmol, ICV, once) causes withdrawal hypothermia and a loss of body weight in morphine-dependent animals.CTOP (0-1.5 nmol per side, Intra-VTA injection) enhances extracellular dopamine levels in the nucleus accumbens and dose-dependently enhances locomotor activity. Animal Model:Male CFLP mice (25-30 g)Dosage:0, 0.001, 0.05, 0.075, 0.1, and 0.5 nmol (made up in artificial cerebrospinal fluid (CSF) and kept in plastic tubes at -25℃ until use)Administration:Intracerebroventricular (i.c.v.) administration, once Result:Antagonized the analgesic effect of morphine in a dose-dependent manner, antagonized.the morphine-induced hypermotility in a dose-dependent manner.Animal Model:Male CFLP mice (25-30 g, Acute dependence to morphine was induced by a single dependence-inducing (100 mg/kg) dose of morphine-HC1)Dosage:0, 0.001, 0.05, 0.2, and 2 nmol Administration:Intracerebroventricular (i.c.v.) administration, once Result:Decreased the body temperature in a dose-dependent manner, and caused withdrawal hypothermia and a loss of body weight in morphine-dependent animals.Animal Model:Long-Evans hooded rats (12, male, 350-450 g) Dosage:0, 0.015, 0.15, and 1.5 nmol per sideAdministration:Intra-VTA (ventral tegmental area) injection Result:Enhanced extracellular dopamine levels in the nucleus accumbens, dose-dependently increased activity, whereas had no effect on feeding and drinking behavior.

——

Endocrinology/Hormones

Opioid Receptor

——

——

——

103429-31-8

1062.28

C50H67N11O11S2

>98% (HPLC)

water:1 mg/mL

[H]N[C@H](CC1=CC=CC=C1)C(=O)N[C@H]1CSSC(C)(C)C(NC(=O)[C@@H](NC(=O)[C@H](CCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC1=O)[C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O

——

(-20℃)

With Ice Pack

≥ 2 years